The role of platelet inhibition in the drug-eluting stent era

Coronary Artery Disease

Volumn 15, Issue 6, 2004, Pages 327-329

  Tamberella, Michael R ^a   Furman, Mark I ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Antiplatelet agents; Drug eluting stents; GPIIb IIIa antagonists; Sirolimus; Stents; Taxol; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ASPIRIN; CORONARY STENOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; STENTS;

EID: 4644341180     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200409000-00005     Document Type: Review

References (21)

1. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-632.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2:349-360. The definitive study demonstrating mortality reduction with aspirin.
3. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Adminstration Cooperative Study. New Engl J Med 1983; 309:396-403.
4. Cairns JA, Gent M, Singer JEA. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian Multicenter Trial. New Engl J Med 1985; 313:1369-1375. The benefits of aspirin in patients with unstable angina.
5. Theroux P, Ouimet H, McCans JEA. Aspirin, heparin, or both to treat acute unstable angina. New Engl J Med 1988; 319:1105-1111.
6. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18:1587-1593.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830.
8. Guyatt G, Schunemann H, Cook D, Jaeschke R, Pauker S, Bucher H. Grades of recommendation for anti-thrombotic agents. Chest 2001; 119:3S-7S.
9. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318:1714-1719.
10. Lembo MJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS, Jr. et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65:422-426.
11. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780. First trial demonstrating reduction in restenosis with use of drug-eluting stents.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323. Largest trial of sirolimus-eluting stents demonstrating a larger patient population the benefits of DES. There is no increase in thrombotic events with DES.
13. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093-1099.
14. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS-I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107:38-42.
15. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-794.
16. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS-III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559-564.
17. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231. Largest trial to date demonstrating reduction in restenosis with a paclitaxel-eluting stent. There is no increase in thrombotic events with DES.
18. Curtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine. In: Michelson AD (Ed.), Platelets. New York: Academic Press; 2002:787-801.
19. Furman MI, Frelinger III AL, Michelson AD. Anti-thrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. Curr Cardiol Rep 2000; 2:386-394.
20. Agah R, Plow EF, Topol EJ. GPIIb-IIIa antagonists. In: Michelson AD (Ed.), Platelets. New York: Academic Press; 2002:769-785.
21. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41:2093-2099.